Rhythm Pharmaceuticals (NASDAQ:RYTM) versus Senti Biosciences (NASDAQ:SNTI) Head to Head Analysis

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Senti Biosciences (NASDAQ:SNTI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

25.7% of Senti Biosciences shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Rhythm Pharmaceuticals and Senti Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-69.03%	-171.16%	-43.00%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Rhythm Pharmaceuticals and Senti Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1	3	18	0	2.77
Senti Biosciences	1	0	1	1	2.67

Rhythm Pharmaceuticals currently has a consensus price target of $142.00, suggesting a potential upside of 29.26%. Senti Biosciences has a consensus price target of $9.00, suggesting a potential upside of 6,022.45%. Given Senti Biosciences’ higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Rhythm Pharmaceuticals.

Valuation & Earnings

This table compares Rhythm Pharmaceuticals and Senti Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76 million	40.14	-$196.54 million	($2.90)	-37.88
Senti Biosciences	$20,000.00	228.95	-$61.44 million	($1.77)	-0.08

Senti Biosciences has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rhythm Pharmaceuticals has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500.

Summary

Senti Biosciences beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.

About Senti Biosciences

Senti Biosciences, Inc. is a biotechnology company developing gene and cell therapies for cancer and other serious diseases. The company’s technology is based on synthetic biology, including programmable gene circuits designed to help engineered immune cells recognize disease-associated targets, respond to specific biological signals and limit activity in healthy tissue. Senti Biosciences applies its platform to the development of engineered cell therapies, including chimeric antigen receptor natural killer (CAR-NK) and other immune-cell programs.